查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1470987

肝纤维化药物市场：按药物类型、分销管道划分 - 全球预测 2024-2030

Liver Fibrosis Drugs Market by Drug Type (Antifibrotic Agents, Antioxidant Inflammation Modulators, Antiviral Drugs), Distribution Channel (Offline Pharmacies, Online Pharmacies) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

肝纤维化药物市场规模预计2023年为142.8亿美元，预计2024年将达155.7亿美元，2030年将达273.8亿美元，复合年增长率为9.74%。

肝纤维化药物是一种旨在预防、阻止或逆转肝纤维化过程的药物。肝纤维化是一种以细胞外基质蛋白（包括胶原蛋白）过度累积为特征的疾病，导致肝组织形成疤痕。如果不及时治疗，这种情况可能会发展为更严重的肝臟疾病，例如肝硬化和肝癌。这些药物旨在破坏纤维化过程、减少发炎和改善肝功能。乙型肝炎、丙型肝炎、非酒精性脂肪性肝炎 (NASH) 和酒精性肝病的盛行率不断上升，强调了对有效治疗方法的需求，包括治疗肝纤维化的药物。製药公司和研究机构增加投资开发新疗法正在扩大肝纤维化治疗的发展。肝纤维化治疗药物的高开发和生产成本阻碍了市场成长。市场成长是由旨在对抗肝病和促进肝臟健康的国际医疗保健计划的提供以及对肝纤维化研究和药物开发的认识和资金的增加所推动的，预计将为肝纤维化研究和药物开发创造机会。

主要市场统计
基准年[2023] 142.8亿美元
预测年份 [2024] 155.7亿美元
预测年份 [2030] 273.8亿美元
复合年增长率（%） 9.74%

药物类型 扩大抗纤维化药物的使用以预防和抑制纤维化

抗纤维化药物是专门设计用于预防或减少肝臟纤维化（疤痕）形成的药物。这些药物透过针对参与细胞外基质蛋白累积的途径发挥作用，从而减缓或逆转纤维化过程。这些药物对于治疗导致肝纤维化的疾病至关重要，并有可能阻止肝硬化和肝功能衰竭的进展。抗氧化发炎调节剂是作用于肝臟内氧化压力和发炎途径的药物。氧化压力和发炎是肝纤维化的主要促进要素，并导致肝损伤的进展。透过调节这些途径，这些药物旨在保护肝臟免受进一步损伤，阻止纤维化过程，并在某些情况下促进现有纤维化的解决。抗病毒药物在肝纤维化的治疗中发挥重要作用，特别是当纤维化是由B型肝炎或C型肝炎等病毒感染引起时。透过有效控製或根除病毒感染，这些药物可以防止引起纤维化的持续肝损伤，并降低严重肝臟疾病（包括肝硬化和肝癌）的风险。免疫调节药物是一种影响免疫系统反应并促进肝纤维化发生和进展的药物。这些药物可以增强或抑制免疫反应的特定成分，旨在减少肝臟的发炎和纤维化活动。其确切作用取决于纤维化的根本原因，使其成为标靶治疗策略的重要组成部分。

分销管道 透过网路药房的 24/7 服务改善肝纤维化药物的获取

线下药局构成了肝纤维化药物的基本分销管道。这些药局位于社区内或社区附近，患者可以轻鬆前往。线下药局，包括独立药局和连锁药局，提供个人化服务和快速取得药物，使其成为许多寻求立即治疗的患者的首选。医院药房专门为医院和临床环境中的住院患者和门诊病人配药。它在分发肝纤维化药物方面发挥着重要作用，特别是对于接受直接医疗护理或需要特定治疗的患者。医院药局满足接受医疗管理的肝纤维化患者的特殊需求，并确保及时、准确的药物传递。零售药局，包括大型药局连锁店和设有药局部门的超级市场，提供广泛的网路来改善药品的取得。零售药局提供多种药品，可供广大民众使用。零售药局利用其广泛的影响力和营运效率，为分销网络做出了重大贡献。网路药局已成为肝纤维化药物不断增长的分销管道，提供便利且价格往往具有竞争力。网路药局迎合那些喜欢将药物直接送到家中的患者，无需前往实体店。网路药局对于行动不便或居住在偏远地区的患者特别有利。

区域洞察

美洲，特别是北美，是肝纤维化药物开发和采用的关键地区。美洲是医药创新、法律规范和医疗保健支出的关键地区，使其成为肝纤维化药物的主要市场。由于肥胖和饮酒等因素，肝病的高盛行率进一步增加了该地区对有效治疗方法的需求。此外，政府和私营部门对肝病研究的大力支持正在支持肝纤维化新的先进治疗方法的开发。由于医疗保健支出的增加、对肝病的认识不断提高以及医疗保健基础设施的改善，亚太地区肝纤维化药物市场正在快速成长。日本、中国、韩国等国家位居前列，其中日本凭藉先进的医疗体系和较高的药物研发率做出了重大贡献。乙型肝炎和丙型肝炎是肝纤维化的主要危险因素，该地区的盛行率相对较高，迫切需要有效的治疗方案。此外，不断增长的中等收入群体越来越有能力负担先进的治疗方法，从而推动了亚太地区肝纤维化药物市场的发展。欧洲、中东和非洲地区的肝纤维化治疗市场呈现多样化的前景。欧洲的特点是强有力的法律规范、广泛的医疗保健以及对肝病的高度认识，使其成为这些治疗方法的主要市场。欧洲肝病研究协会 (EASL)倡议正在加强肝纤维化治疗的前景，进一步提高研究和意识。中东一些国家正在发展医疗基础设施，这可能会扩大肝纤维化治疗的范围。非洲市场的成长受到经济限制的阻碍，但国际卫生组织正在加紧努力，透过教育和治疗计划来改善状况。

FPNV定位矩阵

FPNV定位矩阵对于评估肝纤维化药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对肝纤维化治疗药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.肝纤维化治疗药物市场规模及预测如何？

2.肝纤维化药物市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3.肝纤维化药物市场的技术趋势和法规结构是什么？

4.肝纤维化治疗药物市场主要厂商的市场占有率如何？

5.进入肝纤维化药物市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球慢性肝病盛行率增加
      • 肝纤维化治疗优惠报销政策
    • 抑制因素
      • 配製和开发肝纤维化药物的复杂性
    • 机会
      • 用于新开发的新研究基金
      • 改良肝臟影像技术和肝纤维化生物标记
    • 任务
      • 肝纤维化药物核准的严格法规结构
  • 市场区隔分析
    • 药物类型：增加抗纤维化药物的使用，预防和减少纤维化的形成
    • 分销管道：网上药房的24/7服务改善了肝纤维化药物的获取
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章依药物类型分類的肝纤维化治疗药物市场

  • 抗纤维化剂
  • 抗氧化发炎调节剂
  • 抗病毒药物
  • 免疫调节剂

第七章肝纤维化治疗药物市场：依通路分类

  • 线下药局
  • 网路药房

第八章北美和南美肝纤维化治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区肝纤维化药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲肝纤维化治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 伺服 2 期试验显示，83% 接受治疗的成年人在 MASH 肝病方面取得了突破性成果，纤维化显着改善。
    • 益普生宣布，美国FDA 已对其治疗罕见胆汁淤积性肝病的药物Elafibranor的新药申请给予优先审查。
    • Madrigal Pharmaceuticals 宣布 Resmetirom 新药申请获得 NDA 接受和优先审查，Resmetirom 是一种治疗与肝纤维化相关的 NASH 的药物
  • 战略分析和建议

第十二章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-437A5D08AE2D

[196 Pages Report] The Liver Fibrosis Drugs Market size was estimated at USD 14.28 billion in 2023 and expected to reach USD 15.57 billion in 2024, at a CAGR 9.74% to reach USD 27.38 billion by 2030.

Liver fibrosis drugs are pharmaceutical agents designed to prevent, halt, or reverse the process of liver fibrosis. Liver fibrosis itself is a pathological condition characterized by the excessive accumulation of extracellular matrix proteins, including collagen, which leads to the scarring of liver tissue. This condition can progress to more severe forms of liver disease, such as cirrhosis and liver cancer if left untreated. These drugs aim to disrupt the fibrogenic processes, mitigate inflammation, and improve liver function. The rising incidence of conditions such as hepatitis B and C, non-alcoholic steatohepatitis (NASH), and alcoholic liver disease fuels the need for effective treatments, including liver fibrosis drugs. Rising investments by pharmaceutical companies and research institutions for developing novel therapeutics are expanding the development of liver fibrosis drugs. The high development and production costs of liver fibrosis drugs hamper the growth of the market. The availability of international healthcare programs aimed at combating liver diseases and promoting liver health with increasing awareness and funding for liver fibrosis research and drug development are expected to create opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 14.28 billion
Estimated Year [2024] USD 15.57 billion
Forecast Year [2030] USD 27.38 billion
CAGR (%) 9.74%

Drug Type: Growing usage of antifibrotic agents to prevent and reduce the formation of fibrosis

Antifibrotic agents are specifically designed to prevent and reduce the formation of fibrosis (scarring) in the liver. These drugs work by targeting the pathways involved in the accumulation of extracellular matrix proteins, thereby slowing down or reversing the fibrotic process. They are vital in managing diseases that lead to liver fibrosis, offering a potential means to halt the progression towards cirrhosis and liver failure. Antioxidant inflammation modulators are drugs that act on the oxidative stress and inflammatory pathways within the liver. Oxidative stress and inflammation are key drivers of liver fibrosis, contributing to the progression of liver injury. By modulating these pathways, these agents aim to protect the liver from further damage, halt the fibrotic process, and, in some instances, promote the resolution of existing fibrosis. Antiviral drugs play a crucial role in the management of liver fibrosis, particularly in cases where the fibrosis is caused by viral infections such as Hepatitis B and Hepatitis C. By effectively controlling or eradicating the viral infection, these drugs prevent the ongoing liver damage that triggers fibrosis, thereby reducing the risk of developing severe liver conditions including, cirrhosis or liver cancer. Immune modulators are drugs that influence the immune system's response and contribute to the development and progression of liver fibrosis. These drugs can either enhance or suppress specific components of the immune response, aiming to reduce the inflammatory and fibrogenic activity in the liver. Their precise role varies depending on the underlying cause of fibrosis, making them a critical component of a targeted therapeutic strategy.

Distribution Channel: Improved access to liver fibrosis drugs due to online pharmacies 24*7 services

Offline pharmacies constitute a fundamental distribution channel for liver fibrosis drugs. They are located within or near community settings, providing easy access for patients. Offline pharmacies, including independent and chain pharmacies, offer personalized services and immediate drug availability, making them a preferred option for many patients seeking immediate treatment. Hospital pharmacies specialize in dispensing medications to inpatients and outpatients within a hospital or clinical setting. They play a critical role in the distribution of liver fibrosis drugs, especially for patients receiving direct medical care or those with specific therapeutic needs. Hospital pharmacies ensure the timely and accurate provision of medications, catering to the specialized needs of liver fibrosis patients under medical supervision. Retail pharmacies, including large pharmacy chains and supermarkets with pharmacy departments, offer extensive networks that enhance drug accessibility. They provide liver fibrosis drugs among a wide range of pharmaceutical products, ensuring availability for a broad demographic. Retail pharmacies contribute significantly to the distribution network by leveraging their extensive presence and operational efficiencies. Online pharmacies have emerged as a growing distribution channel for liver fibrosis drugs, offering convenience and often competitive pricing. They cater to patients who prefer having their medications delivered directly to their homes, eliminating the need for physical store visits. Online pharmacies are particularly beneficial for patients with mobility issues or those living in remote areas.

Regional Insights

The Americas, particularly North America, stands as a pivotal region in the development and adoption of liver fibrosis drugs. The Americas represents a significant region in pharmaceutical innovation, regulatory frameworks, and health spending, making it a primary market for liver fibrosis therapies. The high prevalence of liver diseases due to factors such as obesity and alcohol consumption further drives the need for effective treatments in this region. Additionally, strong support for liver disease research from both government and private sectors bolsters the development of new and advanced treatments for liver fibrosis. The Asia-Pacific region is witnessing rapid growth in the liver fibrosis drug market, attributed to increasing healthcare expenditure, growing awareness of liver diseases, and improving healthcare infrastructure. Countries such as Japan, China, and South Korea are at the forefront, with Japan being a significant contributor due to its advanced healthcare system and high rate of pharmaceutical R&D. The prevalence of hepatitis B and C, major risk factors for liver fibrosis, is relatively high in this region, driving the urgency for effective treatment options. Moreover, the expanding middle-class population is increasingly able to afford advanced therapies, thereby boosting the market for liver fibrosis drugs in APAC. The EMEA region presents a diverse outlook on the market for liver fibrosis drugs. Europe is characterized by its strong regulatory frameworks, widespread healthcare access, and high awareness of liver conditions, making it a major market for these therapies. Initiatives by the European Association for the Study of the Liver (EASL) further support research and awareness, enhancing the landscape for liver fibrosis treatment. Certain countries in the Middle East are witnessing growth in healthcare infrastructure, which could lead to increased access to liver fibrosis drugs. Africa's market growth is hindered by economic constraints, but international health organizations are stepping in to improve the situation through educational and treatment programs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Liver Fibrosis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Liver Fibrosis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Liver Fibrosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Arbutus Biopharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Dicerna Pharmaceuticals, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hepion Pharmaceuticals, Inc., Inventiva S.A., LG Life Science Ltd., Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Mirum Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pharmaxis Limited, and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the Liver Fibrosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Antifibrotic Agents
    • Antioxidant Inflammation Modulators
    • Antiviral Drugs
    • Immune Modulators
  • Distribution Channel
    • Offline Pharmacies
      • Hospital Pharmacies
      • Retail Pharmacies
    • Online Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Liver Fibrosis Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Liver Fibrosis Drugs Market?

3. What are the technology trends and regulatory frameworks in the Liver Fibrosis Drugs Market?

4. What is the market share of the leading vendors in the Liver Fibrosis Drugs Market?

5. Which modes and strategic moves are suitable for entering the Liver Fibrosis Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic liver diseases worldwide
      • 5.1.1.2. Favorable reimbursement policies for treatment of liver fibrosis
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity in formulation and development of liver fibrosis drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging research funding for the development of novel liver fibrosis drugs
      • 5.1.3.2. Improvements in liver imaging techniques and biomarkers for liver fibrosis
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory frameworks for drug approval of liver fibrosis
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Growing usage of antifibrotic agents to prevent and reduce the formation of fibrosis
    • 5.2.2. Distribution Channel: Improved access to liver fibrosis drugs due to online pharmacies 24*7 services
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Liver Fibrosis Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antifibrotic Agents
  • 6.3. Antioxidant Inflammation Modulators
  • 6.4. Antiviral Drugs
  • 6.5. Immune Modulators

7. Liver Fibrosis Drugs Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Offline Pharmacies
  • 7.3. Online Pharmacies

8. Americas Liver Fibrosis Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Liver Fibrosis Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Liver Fibrosis Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Survodutide Phase II Trial Shows 83% of Adults Treated Achieved Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis
    • 11.3.2. Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare Cholestatic Liver Disease
    • 11.3.3. Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. LIVER FIBROSIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. LIVER FIBROSIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. LIVER FIBROSIS DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LIVER FIBROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIFIBROTIC AGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIFIBROTIC AGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIOXIDANT INFLAMMATION MODULATORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIOXIDANT INFLAMMATION MODULATORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 283. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023